Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia - A case-based review of clinical management.
Anticoagulation
Cancer
Chemotherapy
Thrombocytopenia
Venous thromboembolism
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
06
10
2020
revised:
16
12
2020
accepted:
18
12
2020
pubmed:
8
1
2021
medline:
22
6
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Patients with cancer undergoing chemotherapy are at risk of thrombocytopenia. The co-incidence of cancer-associated venous thromboembolism (VTE) and thrombocytopenia is a frequent complication in patients with cancer. Especially in certain tumour entities at high VTE risk, chemotherapeutic agents with myelosuppressive effects are part of the standard of care. The management of cancer-associated VTE in the setting of chemotherapy-induced thrombocytopenia is challenging, in the absence of evidence from high-quality studies. Thrombocytopenia is associated with both increased risk of recurrent VTE and risk of bleeding during anticoagulation. In this case-based concise review, we aimed at summarizing available literature and expert consensus guidance on the treatment of cancer-associated VTE in patients with chemotherapy-induced thrombocytopenia.
Identifiants
pubmed: 33412483
pii: S0049-3848(20)30672-1
doi: 10.1016/j.thromres.2020.12.016
pii:
doi:
Substances chimiques
Anticoagulants
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-42Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.